Abiopharma

🔍 Espinoza Octavio (Executive)

Company: LIGAND PHARMACEUTICALS INC (LGND)

Report Date: 2026-08-12

Detailed Transactions and Holdings:

• Acquired 16,179 shares of Common Stock at $52.84 per share (Direct)
  Date: 2026-08-12 | Code: M | equity_swap_involved: 0 | shares_owned_after: 43,875.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 2,074 shares of Common Stock at $70.04 per share (Direct)
  Date: 2026-08-12 | Code: M | equity_swap_involved: 0 | shares_owned_after: 45,949.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 2,869 shares of Common Stock at $55.75 per share (Direct)
  Date: 2026-08-12 | Code: M | equity_swap_involved: 0 | shares_owned_after: 48,818.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 7,171 shares of Common Stock at $57.22 per share (Direct)
  Date: 2026-08-12 | Code: M | equity_swap_involved: 0 | shares_owned_after: 55,989.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 3,348 shares of Common Stock at $68.74 per share (Direct)
  Date: 2026-08-12 | Code: M | equity_swap_involved: 0 | shares_owned_after: 59,337.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 31,641 shares of Common Stock at $292.065 per share (Direct)
  Date: 2026-08-12 | Code: S | equity_swap_involved: 0 | shares_owned_after: 27,696.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 2,869 shares of Employee Stock Option (right to buy) at $55.75 per share (Derivative)
  Date: 2026-08-12 | Code: M | Expires: 2030-02-13 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F3
• Sold 7,171 shares of Employee Stock Option (right to buy) at $57.22 per share (Derivative)
  Date: 2026-08-12 | Code: M | Expires: 2030-10-01 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F4
• Sold 16,179 shares of Non-Qualified Stock Option (right to buy) at $52.84 per share (Derivative)
  Date: 2026-08-12 | Code: M | Expires: 2032-05-05 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F5
• Sold 3,348 shares of Non-Qualified Stock Option (right to buy) at $68.74 per share (Derivative)
  Date: 2026-08-12 | Code: M | Expires: 2029-02-11 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F6
• Sold 2,074 shares of Non-Qualified Stock Option (right to buy) at $70.04 per share (Derivative)
  Date: 2026-08-12 | Code: M | Expires: 2029-02-01 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F7

Footnotes:

• F1: The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 13, 2026, in accordance with Rule 10b5-1.
• F2: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $292.0098 to $292.0846. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F3: The original grant of 4,039 stock options vests and is exercisable as to approximately 15% of the underlying shares on August 13, 2020, approximately 70% of the underlying shares in 28 substantially equal monthly installments beginning on September 13, 2020, and approximately 15% of the underlying shares in 12 substantially equal monthly installments thereafter.
• F4: The stock option vests and is exercisable as to approximately 14% of the underlying shares on April 1, 2021, approximately 73% of the underlying shares in 32 substantially equal monthly installments on May 5, 2021, and approximately 13% of the underlying shares in 10 substantially equal monthly installments thereafter.
• F5: The stock option vests and is exercisable as to approximately 14% of the underlying shares on August 5, 2022, approximately 64% of the underlying shares in 28 substantially equal monthly installments beginning on September 5, 2022, and approximately 22% of the underlying shares in 12 substantially equal monthly installments thereafter.
• F6: The stock option vests and is exercisable as to approximately 13% of the underlying shares on August 11, 2019, and the remaining of the underlying shares in 40 substantially equal monthly installments thereafter.
• F7: The stock option vests and is exercisable as to approximately 16% of the underlying shares on August 1, 2019, approximately 74% of the underlying shares in 28 substantially equal monthly installments beginning on September 1, 2019, and approximately 10% of the underlying shares in 12 substantially equal monthly installments thereafter.